| BRIEF COMMUNICATION |
|
| Year : 2015 | Volume
: 19
| Issue : 5 | Page : 686-690 |
|
|
High-mix insulins
Sanjay Kalra1, Mohammad Hamed Farooqi2, Ali E El-Houni3
1 Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India
2 Dubai Diabetes Center, Dubai Health Authority, Dubai, United Arab Emirates
3 Tawam Medical Campus, Johns Hopkins Medicine; Faculty of Medicine, UAE University, Al Ain, Abu Dhabi, United Arab Emirates
Correspondence Address:
Sanjay Kalra
Department of Endocrinology, Bharti Hospital, Karnal, Haryana
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.163214
|
|
|
Premix insulins are commonly used insulin preparations, which are available in varying ratios of different molecules. These drugs contain one short- or rapid-acting, and one intermediate- or long-acting insulin. High-mix insulins are mixtures of insulins that contain 50% or more than 50% of short-acting insulin. This review describes the clinical pharmacology of high-mix insulins, including data from randomized controlled trials. It suggests various ways, in which high-mix insulin can be used, including once daily, twice daily, thrice daily, hetero-mix, and reverse regimes. The authors provide a rational framework to help diabetes care professionals, identify indications for pragmatic high-mix use. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
